EPS: As of FY2025 Q2, the actual value is USD 0.07.<h3>Segment Revenue</h3><ul><li>Units Sold: 20,000,000 Units at $10.00 per unit, generating gross proceeds of $200,000,000 from the Initial Public Offering (IPO) on January 29, 2025.</li><li>Over-Allotment Option: 3,000,000 additional Units at $10.00 per unit, generating additional gross proceeds of $30,000,000 on February 18, 2025.</li><li>Private Placement Units: 400,000 units at $10.00 per unit, generating $4,000,000, and an additional 30,000 units at $10.00 per unit, generating $300,000.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $2,288,579 for the three months ended June 30, 2025, and $3,543,122 for the six months ended June 30, 2025.</li><li>General and Administrative Costs: $131,919 for the three months ended June 30, 2025, and $462,844 for the six months ended June 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Cash: $822 as of June 30, 2025.</li><li>Net Cash Used in Operating Activities: - $357,899 for the six months ended June 30, 2025.</li><li>Net Cash Used in Investing Activities: - $231,150,000 for the six months ended June 30, 2025.</li><li>Net Cash Provided by Financing Activities: $231,507,370 for the six months ended June 30, 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Interest Earned on Cash and Investments Held in Trust Account: $2,420,498 for the three months ended June 30, 2025, and $4,005,966 for the six months ended June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company intends to focus on companies in the pharmaceutical industry and plans to complete an initial business combination within 15 months from the closing of the IPO (April 29, 2026), which may be extended up to 21 months.</li><li>Non-Core Business: The company has not commenced any operations and will not generate any operating revenues until after the completion of its initial business combination.</li><li>Priority: The company aims to use the funds from the trust account to complete the initial business combination and finance the operations of the target business or businesses.</li></ul>

Drugs Made In America Acquisition - Unit | 10-Q: FY2025 Q2 EPS: USD 0.07